Eindhoven-based MedTech startup ShanX Medtech (SXM), which supplies in-vitro diagnostic platforms for antibiotic susceptibility testing, has closed a €15 million Seed funding spherical to scale, enhance medical validation, and put together for market launch.
The oversubscribed funding spherical consists of a number of funding devices, together with fairness, grants and the Innovatiekrediet. The fairness funding was led by the Borski Fund, NextGen Ventures, CbusineZ (an unbiased funding fund intently related to healthcare insurer CZ), Brabantse Ontwikkelings Maatschappij (BOM), Make investments-NL, and a distinguished strategic angel fund.
The corporate was additionally just lately awarded €8.85 million European Fee Contract (HADEA/2025/CPN/0006), developed by the Well being Emergency Preparedness and Response Authority (DG HERA) in collaboration with the European Well being and Digital Govt Company (HADEA). This brings the entire financing secured by ShanX to €24 million.
Dr Sophia E. Shanko, founder and CEO of ShanX Medtech, mentioned, “We based ShanX Medtech due to a single affected person story, one that exposed how a lot is at stake when diagnostic outcomes arrive too late.
“Our imaginative and prescient is to equip each clinician with the power to behave decisively, guided by diagnostic proof in real-time. This funding brings us considerably nearer to delivering ultra-rapid AST on to each laboratory and point-of-care environments; quicker, easier, and extra accessible than ever earlier than.”
Based in 2019 and based mostly on the Excessive Tech Campus in Eindhoven, ShanX Medtech develops In-Vitro Diagnostic (IVD) options that ship direct-from-sample antimicrobial susceptibility testing (AST).
By utilizing novel chemistry to observe microbial metabolism, SXM claims to ship outcomes inside an hour with restricted person involvement. In line with it, this represents a major enchancment over present strategies, which require educated experience and time to yield actionable outcomes. FLORA™ is the corporate’s proprietary chemical composition that screens pathogen metabolism in real-time.
With this new capital, the corporate goals to speed up the ultimate growth, medical validation, regulatory approval, and industrial launch of the SXM diagnostic platform.
Simone Brummelhuis, Accomplice at Borski Fund, mentioned, “Following an intensive market evaluation of improvements addressing antimicrobial resistance, ShanX’s know-how clearly emerged as best-in-class. Whereas the corporate’s preliminary go-to-market technique focuses on a well-defined ladies’s well being utility in urinary tract infections, the underlying platform gives substantial potential throughout a variety of medical indications.
“We’re proud to help Sophia and her distinctive staff in realising their formidable imaginative and prescient. The oversubscribed financing spherical, along with a number of multi-million-euro industrial contracts, underscores each the energy of the know-how and the founder’s confirmed industrial execution.”
